Utilizing a clinically relevant haploidentical (HI) murine transplant model, lethally irradiated B6D2F1 (H2K b/d ) mice were transplanted with T cell-depleted (TCD) BM from B6CBAF1 (H2K b/k ) mice. We found that administration of IL-15 significantly increases the numbers of CD8 þ T and natural killer (NK) cells in spleen and BM after transplantion without GVHD. Graft-versus-tumor (GVT) potency of the graft was evaluated upon tumor challenge using P815 tumor cells (H2 d ). IL-15 administration without T-cell infusion did not result in any survival improvement. However, IL-15 in combination with very low-dose T-cell infusion (1 Â 10 4 ) significantly increased GVT activity and improved survival in recipients of HI hematopoietic SCT (HSCT). This effect was observed when IL-15 was given at a later time point, rather than immediately following transplantation. IL-15 administration also specifically increased slow-proliferative CD8 þ T-cell proliferation and IFN-g secretion in CD8 þ T cells in recipients of CFSE (carboxyfluorescein succinimidyl ester)-labeled HI T-cell infusion, whereas there was no effect on CD4 þ T-cell proliferation, suggesting the critical effect of IL-15 on CD8 þ T-cell homeostasis in HI host. We conclude that IL-15 can be used for enhancing antileukemia effect of HI-HSCT, which requires presence of donor-derived T cells.
INTRODUCTION IL-15 has been previously shown to increase natural killer (NK) cell number and function in normal mice and recipients of SCT. [1] [2] [3] IL-15 is a pleiotropic cytokine, which has various roles in the innate and adaptive immune systems, including the development, activation, homing and survival of immune effector cells, especially NK, NK-T and CD8 þ T cells. 4 IL-15 was first isolated from a simian kidney epithelial cell line in 1994 by Grabstein et al. 5 and was described as a novel T-cell growth factor with a biological activity similar to IL-2. In the same year, Burton et al. 6 showed that a lymphokine, originally designated IL-T, secreted by an HTLV-1-associated leukemia cell line was able to stimulate T cells and lymphokine-activated cells, and was subsequently found to be identical to IL-15. IL-15 binds to a receptor complex that consists of IL-15 Ra, IL-2 Rb and the gc chain. 5, 7 IL-15 functions as a key regulator of NK development, homeostasis and activity. 8, 9 Absence of NK cell development was shown in IL-15-, IL-15 Ra-and IL-2/IL-15 Rb-deficient mice. [10] [11] [12] IL-15 administration to normal mice or overexpression of IL-15 increases the numbers and percentages of NK cells in the spleen, proliferation and survival of NK cells, as well as their cytolytic activity and cytokine secretion. 13, 14 Haploidentical (HI) SCT broadens the opportunity for allogeneic SCT, and has produced impressive results in patients transplanted in selected centers. [15] [16] [17] [18] [19] The primary approach to HI hematopoietic SCT (HSCT) has been to perform T-cell depletion from the graft to avoid severe GVHD. T-cell depletion techniques have been successful in decreasing GVHD, but higher rates of relapse, graft rejection and increased susceptibility to opportunistic infection have resulted in increased mortality. 18 The strategy to increase lymphoid reconstitution without augmenting GVHD would be a critical step to improve the outcome of HI-HSCT. We hypothesized that IL-15 as a lymphoid growth factor would increase T-cell reconstitution and may affect GVT activity after HI-HSCT. Use of IL-15 in HI transplant models has never been studied, which merits testing in our murine models.
MATERIALS AND METHODS

Mice and BMT
), B6D2F1 (H2K b/d ) and mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice used in BMT experiments were between 10 and 12 weeks of age. BMT protocols were approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University.
BM cells were removed aseptically from femurs and tibias, and T-cell depleted (TCD) by incubation with anti-Thy 1.2 Ab for 30 min at 4 1C, followed by incubation with Low-TOX-M rabbit complement (Cedarlane Laboratories, Hornby, ON, Canada) for 40 min at 37 1C, or alternatively via anti-CD5 magnetic bead depletion (Miltenyi, Auburn, CA, USA). Typical levels of contaminating T cells after C 0 depletion ranged from 0.2 to 0.5% of all BM leukocytes.
Splenic T cells were obtained by positive selection with anti-CD5 Abs conjugated to magnetic beads (Miltenyi). In some cases, CD4 and CD8 T-cell populations were separated out individually (Miltenyi). Cells (5 Â 10 6 BM cells with or without splenic T cells) were resuspended in Dulbecco Modified Eagle's Medium and transplanted by tail vein infusion (0.25 mL total volume) into lethally irradiated recipients on day 0. On day 0 prior to transplantation, recipients received 11-13 Gy TBR (strain-dependent) from a Cell lines, Abs, flow cytometry and cytokines P815 (H2d) cell line was obtained from ATCC (Manassas, VA, USA). Triple gene expressing murine renal cell carcinoma (RENCA) cells were kindly provided by Dr Marcel van den Brink (Memorial Sloan-Kettering Cancer Center, New York, NY, USA). Antimurine CD16/CD32 FcR block (2.4G2) and all of the following fluorochrome-labeled Abs against murine Ags were obtained from BD Pharmingen (San Diego, CA, USA): H2Kd (SF1-1.1), CD3 (500A2), CD4 (RM4-5), CD8 (53-6.7), CD44 (IM7), CD45R/B220 (RA3-6B2), NK1.1 (PK136), GR-1 (RB6-8C5), TNF-a (MP6-XT22), IFN-g (XMG1.2), isotype controls; rat IgG2a-k, hamster IgG1-k.
Flow Cytometry: 10 6 cells/25 mL were incubated at 4 1C with CD16/CD32 FcR block. Subsequently, cells were incubated at 4 1C with Abs. The stained cells were acquired on a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA), or LSRII cytometer (Becton Dickinson) and analyzed with FlowJo software (Treestar, San Carlos, CA, USA).
Recombinant human IL-15 was kindly provided by Amgen (Thousand Oaks, CA, USA). Recombinant human IL-15 was administered intraperitoneally at 2.5 mg per day, as previously described. 3 
Assessment of GVHD
The severity of GVHD was assessed with a clinical GVHD scoring system, as previously described. 20 Briefly, ear-punched animals in coded cages were individually scored every week for five clinical parameters on a scale from 0 to 2: weight loss, posture, mobility, fur and skin. A clinical GVHD index was generated by summation of the five criteria scores (0-10). Survival was monitored daily. Animals with scores of at least 5 were considered moribund and were killed.
Phorbol myristate acetate (PMA)-ionomycin stimulation and intracellular staining Splenocytes were incubated with PMA (10 ng/mL) and ionomycin (2 mM) for 5 h. Brefeldin A was added at a concentration of 10 mg/mL, 2 h following the addition of PMA and ionomycin. Cells were first stained with surface Abs. Cells were then fixed and permeabilized with the BD Cytofix/Cytoperm Kit (BD Biosciences, San Diego, CA, USA), and subsequently stained with intracellular Abs.
CFSE labeling
Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE), as previously described. 21 Briefly, purified T-cells were incubated with CFSE at a final concentration of 2.5 mM in PBS at 37 1C for 15 min. Cells were then washed three times with PBS before i.v. injection.
Statistics
All values shown in graphs represent the mean ± s.e.m. Survival data were analyzed with the Mantel-Cox log-rank test. For all other analysis, nonparametric unpaired Mann-Whitney U-test was used. ) donors. IL-15 was given from days 21-27. Recipient mice harvested at day 28 had 490% donor cell engraftment in the spleen and BM (data not shown), without evidence of GVHD. Flow cytometric analysis of the BM and spleen was performed. BM NK cells were increased in mice treated with IL-15, though CD8 numbers remained constant (Figure 1a) . Splenic NK and CD8 cells were both significantly increased, whereas CD4 numbers remained about the same compared with the control (Figure 1b) .
We then administered either IL-15 or a vehicle control to the recipients of HI-HSCT after low-dose (1 Â 10 4 ) T-cell infusion. BM CD8 þ T-cell numbers statistically increased in IL-15 group compared with the control and T-cell only groups (Figure 1c ). BM NK cell numbers were observed to decrease after T-cell infusion compared with BM alone, but were significantly increased in mice receiving IL-15 ( Figure 1c) . In a similar pattern as observed in the BM, splenic CD8 þ and NK cells are statistically increased in the IL-15 group compared with the control mice and mice receiving vehicle only (Figure 1d ). CD8 þ cells showed higher IFN-g secretion following PMA/ionomycin stimulation in both groups receiving T-cells compared with control groups (Figure 1e ). There was no significant increase in T-cell TNF-a secretion after IL-15 administration (Figure 1e ). To overcome this, the experiment was repeated with 5 Â 10 4 donor T-cell infusion (Figure 2d ). Even in the vehicle-administered control group, this dose of HI-HSCT donor T-cells completely overcame the P815 tumor challenge (Figure 2d ). All mice lived past 90 days and were tracked weekly for changes in weight (Figure 2e ). To disentangle T-cell GVT from any synergistic T-cell and IL-15 GVT effects, the lower dose of T cells was utilized in combination with a delayed IL-15 administration (day þ 7 to þ 14 post transplantation), which significantly improved the GVT effect compared with T cells only or BM transplant controls (Figure 2f ). Using a combination of clinical and post-mortem observations, and GVHD scoring, we can reasonably say that the majority of mice died from tumor (Table 1) . We wanted to confirm the effects of IL-15 on GVT by using another tumor model. Lethally irradiated CB6F1 mice (H2K b/d ) were transplanted with TCD-BM and T cells from B6CBAF1 mice, and challenged with 2 Â 10 5 RENCA tumor cells. We again showed that IL-15 administration increases antitumor activity in this model with 4 months survival of 5 versus 30% in control and IL-15-treated groups, respectively (Figure 2g) , and there was a clear trend in this model; P: 0.08.
IL-15 administration increases homeostatic T-cell proliferation in a HI host
We then evaluated T-cell proliferation kinetics after IL-15 administration by tracking CFSE-labeled T cells in a HI host. Lethally irradiated B6D2F1 mice were transplanted with CFSElabeled B6CBAF1 splenocytes (30 Â 10 6 ), and were administered with either IL-15 or a vehicle control for 3 days after infusion of splenocytes. Mice were then killed on day 3 after cell infusion, and splenocytes were analyzed by flow cytometry. Decreasing CFSE intensity shows cell proliferation (Figure 3) . We have previously shown that homeostatic T-cell proliferation may take place not only in syngeneic host but also in allogeneic host. 22 All T cells can be divided into three different populations in allogeneic host: (i) undivided cells; (ii) slow-proliferative cells and (iii) fastproliferative cells. 22 IL-15 administration apparently increased the percentage of slow-proliferating CD8 þ T cells, whereas CD4 þ T-cell proliferation remained unaffected. Slow-proliferating cells mildly increased their CD44 expression on their surface while keeping high level of CD62L expression, suggesting that IL-15 administration specifically stimulates slow-proliferative memorylike T cells. The percentage of fast-proliferative CD8 þ T cells (CD62L Low /CD44 High ) did not change after IL-15 administration. We then evaluated the cytokine secretion of proliferating T cells in allogeneic setting. We found that IL-15 increased intracellular IFN-g secretion in undivided and slow-proliferative CD8 þ T cells in recipients of CFSE-labeled T cells, whereas there was no change in IFN-g secreting alloreactive/fast-proliferative cell population (Figure 3b ). IFN-g-secreting cells increased to 59% from 43% in slow-proliferating T cells and from 13% to 25% in undivided T cells.
DISCUSSION
Allogeneic HSCT was limited to the patients who had HLAidentical-related donors. To provide options for patients lacking a matched-related donor, registries of unrelated volunteer donors or cord blood units have been established with the hopes of providing a phenotypically well-matched HSC product. The use of HI donors broadens the application of HSCT. Unfortunately, HI-HSCT has traditionally been associated with higher mortality rates as compared with transplants from well-matched donors, limiting its application. As relapse remains the biggest problem specifically in patients with resistant leukemia, enhancing GVL/GVT activity of HI-HSCT without increasing GVHD is critical for improving the outcome of stem cell transplantation. 19 We have shown here that IL-15 increases CD8 þ T and NK-cell number after HI-HSCT, which may improve outcome of the transplant. On the other hand, IL-15 administration by increasing post-transplant T-cell reconstitution might stimulate GVHD development in T-cell replete models. 3, 23 We have demonstrated that post-transplant IL-15 administration enables a very low-dose T-cell infusion to generate antitumor activity, mitigating the risk of GVHD. We have also found that timing is a critical factor for changing the balance of GVL/GVH to GVL direction. We observed similar findings in the second tumor model (RENCA model), and confirmed the effects of IL-15 on GVT activity.
In this study, we show that IL-15 administration is capable of improving GVT effects in a HI-HSCT murine model. GVT activity against P815 tumor cells is mediated by T cells in our murine transplant models. It has been previously shown that P815 tumor cells are not sensitive to NK cell-mediated cytotoxicity. 24 IL-15 halflife is around 1 h after administration, and it should be given daily for the treatment. 25 Human IL-15, which has 73% homology with murine IL-15 in amino-acid sequence, binds murine IL-15R and Increase of GVT activity by IL-15 administration CT Sauter et al IL-2Rb, and is immunologically active in mice. 26 The long-term effects of human IL-15 has been studied in non-human primates, demonstrating that administration of daily IL-15 for 8-14 days resulted in lymphocytosis and leukocytosis, and WBC count returned to normal after discontinuation of IL-15 on day 28. 27 Immunological parameters also returned to baseline on day 28 in the same study.
In this study, the GVT effect was only seen when IL-15 was given at a delayed time point rather than immediately post transplantation, possibly allowing for a certain level of engraftment to take place. Importantly, this was all accomplished using an extraordinarily low donor T-cell dose. Previous studies have demonstrated that IL-15 administration does not aggravate GVHD in combination with a moderate dose of T cells. 3 Here, we use a low T-cell dose that is a full logarithm lower than in the previous studies (1 and 5 Â 10 4 compared with 2.5 and 5 Â 10 5 T cells). In our model, a moderately low T cell (5 Â 10 4 ) completely overcame a P815 tumor challenge, with all groups surviving past day 90. Previous studies using a similar model system (B6 to B6D2) used a T-cell dose of 20-40 times greater to induce GVT, as well as severe GVHD. 28 Our highest dose of T cells in combination with IL-15 induced only a mild chronic GVHD in a small minority of the recipients (Figure 2e and data not shown). Thus, we suggest the possibility to achieve an enhanced immune reconstitution in HI-HSCT conditions using a small dose of mature donor T cells, and homeostatically expanding the CD8 þ T-cell compartment with IL-15.
Interestingly, we have demonstrated here that homeostatic T-cell proliferation can be observed in haplo-matched host, with the same cellular dynamics with allogeneic HSCT. Homeostatic T-cell proliferation including the conversion of naive T-cells to memory phenotype cells is part of the normal T-cell homeostasis, especially for CD8 þ T cells. 29 Immunological response to tumorassociated Ags has been shown that it could be elicited by T-cell homeostatic proliferation in the periphery, involving expansion of T cells recognizing self-MHC/peptide ligands. Dummer et al. 30 reported that sublethally irradiated lymphopenic mice transfused with autologous or syngeneic T-cells demonstrated tumor growth inhibition when challenged with melanoma or colon carcinoma cells. Importantly, the antitumor response depended on homeostatic expansion of a polyclonal T-cell population within lymph nodes, which was associated with CD8 þ T-cell-mediated tumor-specific cytotoxicity and IFNg production. IL-15 administration to syngeneic and allogeneic host increases CD8 þ T-cell survival, and that could result in increased antitumor activity of tumor-specific T cells. 3, 31 We consider that increased homeostatic CD8 þ T-cell population in haplo-matched host would contribute enhancing antitumor activity after HI-HSCT.
We conclude that IL-15 is useful for enhancing the GVT effect without inducing GVHD in a mouse model. Non-human primate studies have recently shown that IL-15 administration expands memory CD8 ( þ ) and CD4 ( þ ) T, and NK cells in the peripheral blood. 27, 32 Early-phase clinical studies are also underway. We believe that IL-15 will have an important role in immunotherapy, especially in improving post-transplant T-cell deficiency.
